Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors

Annals of Surgical Oncology

Volumn 20, Issue 1, 2013, Pages 66-72

  Lafemina, Jennifer ^a   Qin, Li Xuan ^a   Moraco, Nicole H ^a   Antonescu, Cristina R ^a   Fields, Ryan C ^a   Crago, Aimee M ^a   Brennan, Murray F ^a   Singer, Samuel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MESNA; PROTEIN S 100; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; DISEASE SPECIFIC SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; RADIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEOPLASMS, RADIATION-INDUCED; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; YOUNG ADULT;

EID: 84871764535     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2573-2     Document Type: Article

References (23)

1. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228:355-65.
2. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14:1679-89.
3. Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19:878-85.
4. Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249:1014-22.
5. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations. J Surg Oncol. 2008;97:340-9.
6. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311-4.
7. Huson SM, Compston DA, Clark P, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet. 1989;26:704-11.
8. Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med. 1986;314:1010-5.
9. D'Agostino AN, Soule EH, Miller RH. Primary malignant neoplasms of nerves (malignant neurilemomas) in patients without manifestations of multiple neurofibromatosis (Von Recklinghausen's disease). Cancer. 1963;16:1003-14.
10. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;107:1065-74.
11. Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005;23:8422-30.
12. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57:2006-21.
13. Sordillo PP, Helson L, Hajdu SI, Magill GB, Kosloff C, Golbey RB, et al. Malignant schwannoma-clinical characteristics, survival, and response to therapy. Cancer. 1981;47:2503-9.
14. Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma. 2009;2009:756395.
15. Cashen DV, Parisien RC, Raskin K, Hornicek FJ, Gebhardt MC, Mankin HJ. Survival data for patients with malignant schwannoma. Clin Orthop Relat Res. 2004:69-73.
16. deCou JM, Rao BN, Parham DM, Lobe TE, Bowman L, Pappo AS, et al. Malignant peripheral nerve sheath tumors: the St. Jude Children's Research Hospital experience. Ann Surg Oncol. 1995;2:524-9.
17. Hruban RH, Shiu MH, Senie RT, Woodruff JM. Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer. 1990;66:1253-65.
18. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42:351-60.
19. Riad S, Biau D, Holt GE, Werier J, Turcotte RE, Ferguson PC, et al. The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma. Cancer. 2012;118:2682-92.
20. Mavrogenis AF, Pala E, Guerra G, Ruggieri P. Post-radiation sarcomas. Clinical outcome of 52 Patients. J Surg Oncol. 2012;105:570-6.
21. Gladdy RA, Qin LX, Moraco N, Edgar MA, Antonescu CR, Alektiar KM, et al. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol. 2010;28:2064-9.
22. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, USA, July 13-15, 1987. Neurofibromatosis. 1988;1:172-8.
23. Singer S, Maki RG, O'Sullivan B. Soft tissue sarcoma. In: DeVita VTJ, Lawrence TS, Rosenberg SA, et al., eds. Cancer: principles and practice of oncology, 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.